Podcasts about aerie pharmaceuticals

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 26 :58 FDA grants fast track designation to brepocitinib for noninfectious uveitis 1:42  I. Howard Fine, MD, esteemed ophthalmologist, dies 3:54 First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia 5:48 LENZ Therapeutics submits NDA for drops to treat presbyopia 7:57 Intro of Tom Mitro 10:40 Tell us about your journey in ophthalmology 12:38 Tell us about the new dry eye drug from Signal 12. 15:53 How much sensation is on the forehead if the drug is well tolerated? 24:13 What are your thoughts on the current ophthalmology market? 26:01 Tell us a funny story about Jim Mazzo and about John Hovanesian. 28:51 Preview of episode 29 33:25 Give us your feedback 34:34 Thanks 34:50 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Tom Mitro is the president and chief operating officer for Aerie Pharmaceuticals. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Mitro at the time of publication.

Don't miss the latest episode of the OIS Retina Podcast, where we sit down with optometrist and ophthalmology researcher Brian Levy for an illuminating discussion on the future of eye care. In this episode, Brian takes us on a journey through his career, from his early days in vet school to his groundbreaking work at Presbyterian Medical Center, Aerie Pharmaceuticals, Bausch + Lomb and currently at InflammX Therapeutics. Here are some key talking points from the episode: 

Synopsis: Theresa Heah, M.D., is the CEO of Intergalactic Therapeutics. Intergalactic is overcoming the limitations of viral-based gene therapy and developing a best-in-class non-viral alternative. Intergalactic uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA (“C3DNA”) molecules designed to provide a potentially safer and more effective solution for patients. Theresa has over two decades of global drug development and commercial experience. She talks about her choice to focus on ophthalmology, where ophthalmology as a therapeutic area is from a drug development perspective, and some of the opportunities she sees ahead for this space. She discusses the importance of having mentors and the emotional aspects of being a CEO. Finally, she dives into the work Intergalactic is doing, where they are from a company building perspective, and how she thinks about driving more access and scale for gene therapies, given the high cost of development and scalability. Since this podcast was recorded, in July 2023, new data from IG-002, Intergalactic's lead program, demonstrated persistent ABCA4 expression in non-human primate retinas over six months after a single administration.This data support plans to advance IG-002 into Phase 1 trials in 2024. Biography: Dr. Heah is an accomplished executive who brings over two decades of drug development and commercial experience, focused primarily in gene therapy and ophthalmology. She most recently served as President and Chief Medical Officer at Kriya Therapeutics, where she launched the ophthalmology division, Kriya Ophthalmology, and was responsible for building its AAV gene therapy portfolio strategy and supporting the company's Series C financing. Prior to joining Kriya, Dr. Heah served as Executive Vice President of Operations and Chief Medical Officer at AsclepiX Therapeutics, where she led the company's Series A financing and advancement of its pipeline products into the clinic. Dr. Heah also previously served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), working to develop gene therapies in ophthalmology and rare diseases. In addition, she has held several leadership positions with increasing responsibility in early-stage private companies (Fovea Pharmaceuticals) and publicly traded companies (Aerie Pharmaceuticals, Allergan, Bayer Healthcare, Sanofi). Dr. Heah earned her M.D. from Guy's, King's and St. Thomas' School of Medicine, King's College, University of London, and her Executive Master's in Business Administration from the European School of Management & Technology (ESMT), Berlin.

Hoy tenemos la suerte de entrevistar a Patrick Tresserras, uno de los pocos emprendedores en serie de nuestro ecosistema. Patrick es fundador de dos empresas en el campo de las enfermedades de la superfície ocular. La primera de ellas es Avizorex Pharma, la cual creó junto a Carlos Belmonte. Avizorex fue una spin-off que se centró en el desarrollo de un tratamiento para el síndrome del ojo seco. Años más tarde, Avizorex fue adquirida por la multinacional Aerie Pharmaceuticals, que actualmente forma parte de Alcon. Y ahora, Innerva Pharmaceuticals, también junto a Carlos Belmonte e Inveready. Innerva es una start-up enfocada en el desarrollo de un tratamiento para el dolor ocular post-quirúrgico. ¡Estamos seguros que el episodio de hoy te va a encantar! La música que escucharás en este podcast es: Obra: Instinto Animal Música de https://www.fiftysounds.com/es/ Obra: Planeta Líquido Música de https://www.fiftysounds.com/es/ Obra: Futuro Asombroso Música de https://www.fiftysounds.com/es/

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, sit down with Gavin Herbert, Tom Burns, Andy Corley and Tom Mitro to discuss their days at Allergan and what they have learned from their experiences. Welcome to the Eyeluminaries podcast :37 News and notes with John and Jim 1:01 Viatris to acquire Oyster Point, Famy Life Sciences 1:06 Ocuphire enters global license agreement with Famy for Nyxol development 4:20 Eyenuk secures $26 million in Series A funding 6:24 Encapsulated cell therapy shows positive results for macular telangiectasia 8:31 Introduction of the Allergan alumni 10:35 The interview 12:10 Gavin Herbert – what is the secret to great leadership? 12:18 Tom Burns – what have you learned from Allergan that has led to your success? 17:48 Andy Corley 20:38 Tom Mitro 24:50 Jim Mazzo 29:41 Herbert – principles 30:29 Corley – producing jobs 32:01 Herbert – alumni 32:50 Wrap up and a preview of episode 10 33:38 Feedback, questions and guest suggestions at eyeluminaries@healio.com 34:06 Thanks for listening 34:14 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Gavin Herbert is a board member of the Doheny Eye Institute and the Nixon Foundation, as well as a life trustee of the University of Southern California. He was the co-founder and chief executive officer of Allergan Inc. Tom Mitro is the past president and chief operating officer at Aerie Pharmaceuticals. Tom Burns serves as the chief executive officer and the chairman of the board for Glaukos. Andy Corley is the founder of Yelroc Consulting, Inc. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Herbert reports being a board member of the Doheny Eye Institute and the Nixon Foundation, as well as a life trustee of the University of Southern California. He was the co-founder and chief executive officer of Allergan Inc. Mitro is the past president and chief operating officer at Aerie Pharmaceuticals. Burns serves as the chief executive officer and the chairman of the board for Glaukos. Corley is the founder of Yelroc Consulting, Inc.

The global ophthalmic drugs market is estimated to attain a valuation of US$ 50.2 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.83% during the forecast period, 2022 to 2031.The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the ophthalmic drugs industry. The current and historical status of the market together with forecasted market size and trends are demonstrated in the assessment in simple manner. In addition, the report delivers data on the volume, share, revenue, production, and sales in the market.The report by TMR is the end-product of a study performed using different methodologies including the PESTEL, PORTER, and SWOT analysis. The study with the help of these models shed light on the key financial considerations that players in the ophthalmic drugs market need to focus on identifying competition and formulate their marketing strategies for both consumer and industrial markets. The report leverages a wide spectrum of research methods including surveys, interviews, and social media listening to analyze consumer behaviours in its entirety.Get Sample Copy of the Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1769Ophthalmic Drugs Market: Industry Trends and Value ChainThe study on the ophthalmic drugs market presents a granular assessment of the macroeconomic and microeconomic factors that have shaped the industry dynamics. An in-depth focus on industry value chain help companies find out effective and pertinent trends that define customer value creation in the market. The analysis presents a data-driven and industry-validated frameworks for understanding the role of government regulations and financial and monetary policies. The analysts offer a deep-dive into the how these factors will shape the value delivery network for companies and firms operating in the market.Ophthalmic Drugs Market: Branding Strategies and Competitive StrategiesSome of the key questions scrutinized in the study are:What are some of the recent brand building activities of key players undertaken to create customer value in the ophthalmic drugs market?Which companies are expanding litany of products with the aim to diversify product portfolio?Which companies have drifted away from their core competencies and how have those impacted the strategic landscape of the ophthalmic drugs market?Which companies have expanded their horizons by engaging in long-term societal considerations?Which firms have bucked the pandemic trend and what frameworks they adopted to stay resilient?What are the marketing programs for some of the recent product launches?Make Inquiry before Buying – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1769The list of key players operating in the ophthalmic drugs market includes following names:Aerie Pharmaceuticals, Inc.Allergan plcValeant Pharmaceuticals International, Inc.Bayer AGGenentech, Inc. (F. Hoffmann-La Roche Ltd.)Novartis AGPfizer Inc.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Sean Ianchulev, MD, MPH. Welcome to the Eyeluminaries podcast :01 A review of the previous episode :23 News and notes with John and Jim 1:31 Alcon to acquire Aerie Pharmaceuticals 1:40 Glaukos, iVeena enter licensing agreement for keratoconus treatment 5:20 Lions Eye Institute to acquire SightLife 8:37 Novaliq submits NDA for CyclASol for treatment of dry eye disease 11:37 AbbVie, iSTAR enter alliance to support MINIject MIGS device 13:30 Introduction of Sean Ianchulev 16:30 The interview 18:37 Impact on Google Glass 21:32 What innovations are you proud of and what projects are you excited about? 26:20 What advice do you have for new entrepreneurs? 33:04 How do you balance your work life and your home life? 36:24 Legends in the field of ophthalmology 38:07 Give feedback at eyeluminaries@healio.com 39:39 A preview of the next episode of Eyeluminaries 39:54 Thanks for listening 40:26 Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can find Dr. Ianchulev on LinkedIn: Sean Ianchulev, MD, MPH. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

A new generation of drug delivery technology is emerging, with new refillable, absorbable, and dissolvable drug delivery systems making their way through clinical trials and into the market. Large pharmaceutical companies, biotech firms, and device startups alike are all developing innovative alternatives to intravitreal injection.These systems are important for improving compliance and, as a result, patient outcomes. The ability to extend treatment duration also alleviates some of the patient and physician burden that comes with regular injections.To explore the latest advances in the ocular drug delivery space and their impact on patients and clinics, OIS brought together an A team of medical, venture capital, and industry experts.Listen to this podcast to hear our panel discuss: • Do longer-lasting therapies, injectables, and resorbables represent a new bar for existing technologies?• What's in development at Bausch + Lomb, Aerie Pharmaceuticals, and Allergan/Abbvie?• How will these new delivery systems change the dynamics in the clinic?• What should companies starting to commercialize keep in mind to ensure success?

How Origin Materials (ORGN) makes plastic out of wood chips with co-CEOs John Bissell and Rich Riley. Laureate Education (LAUR) focuses its business on Mexico and Peru. A failed drug test that might actually not be a failure for Aerie Pharmaceuticals (AERI). Buy now, pay later fintech company GreenSky (GSKY) gets Goldman Sachs' attention. The Drill Down with Cory Johnson offers a daily look at the business stories behind stocks on the move. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this week’s episode of the OIS Podcast, Robert Rothman, MD, is joined by Vince Anido, Chairman and CEO of Aerie Pharmaceuticals. Vince shares his vision for Aerie, and how his lean, efficient team carefully strategizes every move they make to cultivate products that benefit patients. We learn background on both Vince and Aerie, and how two of Aerie’s products, Rhopressa and Rocklatane, were brought to market in under one year. How has Aerie has made a name for themselves globally within glaucoma, and next in dry eye, and retina?

This week we veer off the beaten path to bring you a unique panel discussion with industry leaders from Allergan, Santen, Genentech, and Aerie Pharmaceuticals. Each share expertise on drug development technologies and discusses insights on some of the hurdles they have had to overcome to successfully roll out products in pharma.

Prior to joining AsclepiX Therapeutics, Dr. Heah served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), where she worked on developing ophthalmic gene therapies. Before her tenure at AGTC, Dr. Heah was Vice President, Global Head of Clinical Research, Medical and Professional Affairs at Aerie Pharmaceuticals, where she played a key role in driving growth and success of the organization globally. In this position, Dr. Heah was responsible for global strategy and development of ophthalmology programs, leading an experienced team executing clinical research, clinical operations, medical affairs, and professional affairs. During her tenure, she successfully expanded her global team size from 10 to 52 professionals and took a leading role in Aerie’s pharmaceutical development program for milestone product candidates, including Rhopressa® and Rocklatan®.Prior to her tenure at Aerie, Dr. Heah served with increasing responsibility, initially as the Director, Senior Global Medical Affairs Physician lead in the worldwide launch of EYLEA® followed by the role of Global Strategic Marketing Director at Bayer Healthcare Pharmaceuticals, where she served as the brand plan lead for EYLEA, an anti-VEGF compound indicated for the management of 5 retinal diseases. As part of her work on EYLEA, Dr. Heah oversaw the development of brand strategy, positioning, market research, advisory boards, key message development, pricing & reimbursement, and promotional campaigns. While at Bayer, her product portfolio’s value exceeded €1B annually. Dr. Heah has clinical experience as an ophthalmologist in the U.K. Dr. Heah earned her Doctorate of Medicine from Guy’s Kings and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in Business Administration from the European School of Management & Technology (ESMT), Berlin.

In this episode, we bring you pearls and perspectives from Hawaiian Eye 2020.    Ashley Brissette, MD, MSc, FRCSC, considers the importance of testing for inflammation and dry eye before performing cataract surgery :17 Ryan Bleeks, of Sun Ophthalmics, shares an update on Cequa - cyclosporine ophthalmic solution 0.09% - for the treatment of dry eye disease 2:45 Jay S. Pepose, MD, PhD, discusses treatment options for varicella zoster 4:04 Jennifer M. Loh, MD, discusses the impact that sharing a meibomian gland image can have in patient treatment 6:04 Brandon Ayres, MD, examines the use of the FDA-approved epi-off corneal cross-linking procedure 7:16 John P. Berdahl, MD, discusses the benefits of compounded medications that are unique to ophthalmology 10:18 Femida Kherani, MD, shares pearls for incorporating dermal fillers and neuromodulators 12:13 Craig N. Piso, PhD, shares pearls for improving ophthalmic technician performance 13:01 Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses results of the MOST phase 4 trial 14:30 Richard S. Davidson, MD, discusses surgical correction for keratoconus 15:43 Steven D. Vold, MD, discusses the use of Vyzulta -latanoprostene bunod ophthalmic solution 0.024% by Bausch + Lomb 17:00 Thanks for listening 18:45 Disclosures: Ayres reports being a paid consultant to Glaukos. Bleeks is an employee of Sun Ophthalmics. Brissette reports being a paid consultant to Alcon and Zeiss. Loh reports being a paid consultant to Sight Sciences. Mitro is president and COO of Aerie Pharmaceuticals. Vold reports being a paid consultant to Bausch + Lomb. Davidson, Kherani, Pepose and Piso report no relevant financial disclosures.

Tom Mitro of Aerie Pharmaceuticals opens up to OIS Podcast host Ehsan Sadri, MD, about the company’s key programs, including the Phase II trial of netarsudil ophthalmic solution for treatment of open-angle glaucoma.

The goal of the late Dave Epstein was to find a drug that treats the cause of glaucoma by improving trabecular meshwork outflow. After many years of research, Aerie Pharmaceuticals was formed and refined a Rho Kinase inhibitor called Netarsudil. In April 2018 this came to market as Rhopressa and March 2019, combined with latanoprost, as Roclatan. Today I’m talking with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals…and we’re Talking About Glaucoma.Talking About Glaucoma is a podcast of indeterminate frequency and duration. It’s available for free on Apple Podcasts, Google Podcasts, PocketCasts, and many other podcast services. Please rate the podcast on Apple Podcasts and tell your friends about it, so that it can reach more listeners. Drop me a line at podcast@iguy.org with your show ideas.—————————————————————————Selected links:https://aeriepharma.com/https://clinicaltrials.gov/ct2/show/NCT02246764—————————————————————————Production information:This episode was recorded March 2019 during the Annual Meeting of the American Glaucoma Society in San Francisco using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were completed June 2019 on an iMac using Hindenberg Journalist Pro software. Narration was overdubbed using a Blue Yeti Microphone.Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.Robert M Schertzer, MD, MEd, FRCSCpodcast@iguy.orgTwitter - http://twitter.com/robschertzeror http://iguy.tv/twitterBlog - http://wholelottarob.comor http://iguy.tv/blogFacebook - http://facebook.com/talkingaboutglaucomaOffice website - http://westcoastglaucoma.comor http://iguy.tv/officeTheme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr© 2019 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC—————————————————————————Today’s guest:Richard A. Lewis, MDSacramento Eye Consultants1515 River Park Drive, Suite 100, Sacramento, CA 95815Tel: 1-916-649-1515rlewiseyemd@yahoo.comhttps://www.sacramentoeyeconsultants.com/sacramento/our-doctors/richard-a-lewis-md.htm—————————————————————————

The goal of the late Dave Epstein was to find a drug that treats the cause of glaucoma by improving trabecular meshwork outflow. After many years of research, Aerie Pharmaceuticals was formed and refined a Rho Kinase inhibitor called Netarsudil. In April 2018 this came to market as Rhopressa and March 2019, combined with latanoprost, as Roclatan. Today I'm talking with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals…and we're Talking About Glaucoma.Talking About Glaucoma is a podcast of indeterminate frequency and duration. It's available for free on Apple Podcasts, Google Podcasts, PocketCasts, and many other podcast services. Please rate the podcast on Apple Podcasts and tell your friends about it, so that it can reach more listeners. Drop me a line at podcast@iguy.org with your show ideas.—————————————————————————Selected links:https://aeriepharma.com/https://clinicaltrials.gov/ct2/show/NCT02246764—————————————————————————Production information:This episode was recorded March 2019 during the Annual Meeting of the American Glaucoma Society in San Francisco using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were completed June 2019 on an iMac using Hindenberg Journalist Pro software. Narration was overdubbed using a Blue Yeti Microphone.Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.Robert M Schertzer, MD, MEd, FRCSCpodcast@iguy.orgTwitter - http://twitter.com/robschertzeror http://iguy.tv/twitterBlog - http://wholelottarob.comor http://iguy.tv/blogFacebook - http://facebook.com/talkingaboutglaucomaOffice website - http://westcoastglaucoma.comor http://iguy.tv/officeTheme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr© 2019 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC—————————————————————————Today's guest:Richard A. Lewis, MDSacramento Eye Consultants1515 River Park Drive, Suite 100, Sacramento, CA 95815Tel: 1-916-649-1515rlewiseyemd@yahoo.comhttps://www.sacramentoeyeconsultants.com/sacramento/our-doctors/richard-a-lewis-md.htm—————————————————————————

Today in FirstWord:

Aerie Pharmaceuticals scored an impressive win at the recent FDA advisory panel, getting a thumbs up for the approval of Rhopressa. In this interview, CEO Vince Anido explains how Aerie plans to move forward with its lead glaucoma product. He also tells how its new drug-delivery technology will fit into its plans. In addition, we get an update on the late-stage trials of Roclatan.

Today in FirstWord:

Today in FirstWord:

In this interview, Tom Mitro, COO of Aerie Pharmaceuticals, says new hires brought on to prepare for likely commercial sale of Rhopressa bring new life and energy into a company hitting its stride. He also provides to OIS@ASCRS an update on the firm’s glaucoma pipeline.

Today in FirstWord:

Vicente Anido, Jr., PhD’s career has taken him through large companies and private start-ups. He’s taken life science companies public on two occasions, and he’s seen nearly every perspective of the ophthalmology industry. Today, Anido expects big things for Aerie Pharmaceuticals, a clinical-stage pharmaceutical company with two promising treatments for glaucoma in late clinical trials.